{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:45:41Z","timestamp":1784349941217,"version":"3.55.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.intimp.2024.112189","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T22:47:13Z","timestamp":1715899633000},"page":"112189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Precision medicine for severe asthma \u2013 Biological targeted therapy"],"prefix":"10.1016","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2148-1080","authenticated-orcid":false,"given":"Bingqing","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunlu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangtao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2024.112189_b0005","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jaip.2022.11.025","article-title":"Association between blood eosinophils and neutrophils with clinical features in adult-onset asthma","volume":"11","author":"Flinkman","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.intimp.2024.112189_b0010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1149203","article-title":"T-helper cells and their cytokines in pathogenesis and treatment of asthma","volume":"14","author":"Ji","year":"2023","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112189_b0015","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1378\/chest.12-0598","article-title":"T helper 17 cells in airway diseases: from laboratory bench to bedside","volume":"143","author":"Halwani","year":"2013","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.intimp.2024.112189_b0020","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jaip.2018.10.016","article-title":"The severe asthma network in Italy: findings and perspectives","volume":"7","author":"Heffler","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"2","key":"10.1016\/j.intimp.2024.112189_b0025","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.intimp.2024.112189_b0030","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/thx.2010.135574","article-title":"A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils)","volume":"67","author":"Petsky","year":"2012","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.intimp.2024.112189_b0035","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0002-9343(02)01047-1","article-title":"Association of forced expiratory volume with disease duration and sputum neutrophils in chronic asthma","volume":"112","author":"Little","year":"2002","journal-title":"Am. J. Med."},{"key":"10.1016\/j.intimp.2024.112189_b0040","first-page":"118","article-title":"Understanding the immunology of asthma: Pathophysiology, biomarkers, and treatments for asthma endotypes","volume":"36","author":"Gans","year":"2020","journal-title":"Paediatr. Respir. Rev."},{"issue":"11","key":"10.1016\/j.intimp.2024.112189_b0045","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1111\/all.15054","article-title":"Advances and highlights in asthma in 2021","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"issue":"168","key":"10.1016\/j.intimp.2024.112189_b0050","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0193-2022","article-title":"Cytokine-targeted therapies for asthma and COPD","volume":"32","author":"Schleich","year":"2023","journal-title":"Eur. Respir. Rev."},{"issue":"5","key":"10.1016\/j.intimp.2024.112189_b0055","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications","volume":"184","author":"Dweik","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"18","key":"10.1016\/j.intimp.2024.112189_b0060","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJMra071371","article-title":"Leukotrienes","volume":"357","author":"Peters-Golden","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.intimp.2024.112189_b0065","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/ACI.0000000000000284","article-title":"Biologic therapy in the management of asthma","volume":"16","author":"McCracken","year":"2016","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2024.112189_b0070","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/all.14668","article-title":"Real-life study in non-atopic severe asthma patients achieving disease control by omalizumab treatment","volume":"76","author":"Campo","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.intimp.2024.112189_b0075","article-title":"Omalizumab for asthma in adults and children","volume":"1","author":"Normansell","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"8","key":"10.1016\/j.intimp.2024.112189_b0080","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1136\/thoraxjnl-2017-210017","article-title":"Spanish Omalizumab Registry. Duration of the efficacy of omalizumab after treatment discontinuation in 'real life' severe asthma","volume":"73","author":"Vennera","year":"2018","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.intimp.2024.112189_b0085","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nri3341","article-title":"Eosinophils: changing perspectives in health and disease","volume":"13","author":"Rosenberg","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"13","key":"10.1016\/j.intimp.2024.112189_b0090","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.intimp.2024.112189_b0095","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.intimp.2024.112189_b0100","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir. Med."},{"issue":"9842","key":"10.1016\/j.intimp.2024.112189_b0105","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.intimp.2024.112189_b0110","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/cea.13613","article-title":"Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype","volume":"50","author":"Pelaia","year":"2020","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.intimp.2024.112189_b0115","doi-asserted-by":"crossref","DOI":"10.1177\/1753466620929231","article-title":"Switching from omalizumab to mepolizumab: real-life experience from Southern Italy","volume":"14","author":"Carpagnano","year":"2020","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2024.112189_b0120","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.jaip.2020.12.013","article-title":"Optimizing omalizumab dosing in severe asthma-the exploration of therapeutic drug monitoring","volume":"9","author":"Kroes","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"5","key":"10.1016\/j.intimp.2024.112189_b0125","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.jaci.2016.07.038","article-title":"Cardiovascular and cerebrovascular events among patients receiving omalizumab: results from EXCELS, a prospective cohort study in moderate to severe asthma","volume":"139","author":"Iribarren","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2024.112189_b0130","unstructured":"CINQAIR. Prescribing Information. Teva Respiratory. February 2020. Available online: https:\/\/www.cinqair.com\/globalassets\/cinqair\/prescribinginformation.pdf (accessed on 1 January 2022)."},{"issue":"9","key":"10.1016\/j.intimp.2024.112189_b0135","first-page":"564","article-title":"Reslizumab (Cinqair): an Interleukin-5 antagonist for severe asthma of the eosinophilic phenotype","volume":"42","author":"Hom","year":"2017","journal-title":"P t."},{"key":"10.1016\/j.intimp.2024.112189_b0140","unstructured":"CTG Labs\u2014NCBI. A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients with Eosinophilic Asthma; Teva Branded Pharmaceutical Products R&D, Inc.: West Chester, PA, USA, 2021. Available online: https:\/\/beta.clinicaltrials.gov\/study\/NCT01285323?tab=results#publications (accessed on 12 January 2022)."},{"key":"10.1016\/j.intimp.2024.112189_b0145","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4839230","article-title":"Benralizumab: from the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma","volume":"2018","author":"Pelaia","year":"2018","journal-title":"Biomed Res. Int."},{"issue":"2","key":"10.1016\/j.intimp.2024.112189_b0150","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-world effectiveness of benralizumab in severe eosinophilic asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest"},{"issue":"10056","key":"10.1016\/j.intimp.2024.112189_b0155","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.intimp.2024.112189_b0160","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","article-title":"Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial","volume":"9","author":"Harrison","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"25","key":"10.1016\/j.intimp.2024.112189_b0165","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.intimp.2024.112189_b0170","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","article-title":"Benralizumab, an anti-interleukin 5 receptor \u03b1 monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study","volume":"2","author":"Castro","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.intimp.2024.112189_b0175","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2147\/JAA.S312123","article-title":"Real-world experience with Dupilumab in severe asthma: one-year data from an Italian named patient program","volume":"14","author":"Campisi","year":"2021","journal-title":"J Asthma Allergy"},{"issue":"1","key":"10.1016\/j.intimp.2024.112189_b0180","first-page":"797","article-title":"Early effectiveness of type-2 severe asthma treatment with Dupilumab in a real-life setting; a FeNO-driven choice that leads to winning management","volume":"17","author":"Carpagnano","year":"2022","journal-title":"Multidiscip Respir. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112189_b0185","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.anai.2021.04.011","article-title":"Real-world efficacy and safety of Dupilumab use in the treatment of asthma","volume":"127","author":"Nowsheen","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.intimp.2024.112189_b0190","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2147\/JAA.S357548","article-title":"Real-world effectiveness of Dupilumab for patients with severe asthma: a retrospective study","volume":"15","author":"Numata","year":"2022","journal-title":"J. Asthma Allergy"},{"issue":"Suppl. 62","key":"10.1016\/j.intimp.2024.112189_b0195","first-page":"PA1124","article-title":"Dupilumab improves asthma-related patient reported outcomes in asthma patients with chronic rhinosinusitis or nasal polyposis (CRS\/NP) in Liberty Asthma Quest","volume":"52","author":"Corren","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"26","key":"10.1016\/j.intimp.2024.112189_b0200","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.intimp.2024.112189_b0205","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112189_b0210","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","article-title":"Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir. Med."},{"issue":"24","key":"10.1016\/j.intimp.2024.112189_b0215","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa2106567","article-title":"Dupilumab in children with uncontrolled moderate-to-severe asthma","volume":"385","author":"Bacharier","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.intimp.2024.112189_b0220","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00260-2020","article-title":"Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics","volume":"56","author":"Porsbjerg","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.intimp.2024.112189_b0225","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41577-022-00735-y","article-title":"Role of thymic stromal lymphopoietin in allergy and beyond","volume":"23","author":"Ebina-Shibuya","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"19","key":"10.1016\/j.intimp.2024.112189_b0230","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl. J. Med."},{"issue":"10","key":"10.1016\/j.intimp.2024.112189_b0235","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.intimp.2024.112189_b0240","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S2213-2600(21)00537-3","article-title":"Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir. Med."},{"issue":"11","key":"10.1016\/j.intimp.2024.112189_b0245","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3390\/jpm13111594","article-title":"Combination of biological therapy in severe asthma: where we are?","volume":"13","author":"Carriera","year":"2023","journal-title":"J Pers Med."},{"issue":"3","key":"10.1016\/j.intimp.2024.112189_b0250","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jaci.2009.12.935","article-title":"Increased IL-33 expression by epithelial cells in bronchial asthma","volume":"125","author":"Pr\u00e9fontaine","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2024.112189_b0255","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.4049\/jimmunol.0802387","article-title":"Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells","volume":"183","author":"Pr\u00e9fontaine","year":"2009","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112189_b0260","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/cts.13157","article-title":"Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first-in-human and first-in-patient trials","volume":"15","author":"Kosloski","year":"2022","journal-title":"Clin. Transl. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2024.112189_b0265","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/resp.12299","article-title":"Mechanisms of pathogenesis in allergic asthma: role of interleukin-23","volume":"19","author":"Li","year":"2014","journal-title":"Respirology"},{"issue":"2","key":"10.1016\/j.intimp.2024.112189_b0270","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000336418","article-title":"Serum IL-23 strongly and inversely correlates with FEV1 in asthmatic children","volume":"159","author":"Ciprandi","year":"2012","journal-title":"Int. Arch. Allergy Immunol."},{"issue":"18","key":"10.1016\/j.intimp.2024.112189_b0275","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1056\/NEJMoa2030880","article-title":"Risankizumab in Severe Asthma - A Phase 2a","volume":"385","author":"Brightling","year":"2021","journal-title":"Placebo-Controlled Trial. N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2024.112189_b0280","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.prostaglandins.2017.08.006","article-title":"The therapeutic potential of CRTH2\/DP2 beyond allergy and asthma","volume":"133","author":"Jandl","year":"2017","journal-title":"Prostaglandins Other Lipid Mediat."},{"issue":"3","key":"10.1016\/j.intimp.2024.112189_b0285","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaci.2021.03.044","article-title":"Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial","volume":"148","author":"Kelsen","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2024.112189_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104490","article-title":"New treatments for asthma: From the pathogenic role of prostaglandin D2 to the therapeutic effects of fevipiprant","volume":"155","author":"Pelaia","year":"2020","journal-title":"Pharmacol. Res."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924007070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924007070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T14:03:47Z","timestamp":1735308227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924007070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":58,"alternative-id":["S1567576924007070"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112189","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision medicine for severe asthma \u2013 Biological targeted therapy","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112189","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112189"}}